The Medical Letter on Drugs and Therapeutics
Drugs for ADHD
January 27, 2020 (Issue: 1590)Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that...more
- HM Feldman and MI Reiff. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 2014; 370:838.
- ND Volkow and JM Swanson. Clinical practice: adult attention deficit-hyperactivity disorder. N Engl J Med 2013; 369:1935.
- S Dalsgaard et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015; 385:2190.
- SE McCabe et al. Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: a multi-cohort national study. J Am Acad Child Adolesc Psychiatry 2016; 55:479.
- Z Chang et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry 2014; 71:319.
- P Lichtenstein et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367:2006.
- E Chan et al. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA 2016; 315:1997.
- ML Wolraich et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2019; 144:e20192528.
- D Coghill et al. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry 2013; 13:237.
- QuilliChew ER – extended-release chewable methylphenidate tablets. Med Lett Drugs Ther 2016; 58:68.
- Cotempla XR-ODT – another long-acting methylphenidate for ADHD. Med Lett Drugs Ther 2017; 59:183.
- Quillivant XR – an extended-release oral suspension of methylphenidate. Med Lett Drugs Ther 2013; 55:10.
- Transdermal methylphenidate (Daytrana) for ADHD. Med Lett Drugs Ther 2006; 48:49.
- Jornay PM – evening-dosed methylphenidate for ADHD. Med Lett Drugs Ther 2019; 61:126.
- Two new amphetamines for ADHD. Med Lett Drugs Ther 2016; 58:80.
- A new amphetamine oral suspension (Adzenys ER) for ADHD. Med Lett Drugs Ther 2018; 60:e106.
- RH Weisler et al. Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled, forced-dose clinical study. CNS Drugs 2017; 31:685.
- M Brams et al. SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: results of a randomized, double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 2018; 28:19.
- Lisdexamfetamine dimesylate (Vyvanse) for ADHD. Med Lett Drugs Ther 2007; 49:58.
- D Elbe et al. Focus on lisdexamfetamine: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2010; 19:303.
- JH Newcorn et al. Randomized, double-blind, placebo-controlled acute comparator trials of lisdexamfetamine and extended-release methylphenidate in adolescents with attention-deficit/hyperactivity disorder. CNS Drugs 2017; 31:999.
- SC Cohen et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2015; 54:728.
- JM Swanson et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 2017; 58:663.
- LV Moran et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019; 380:1128.
- L Hennissen et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs 2017; 31:199.
- WO Cooper et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365:1896.
- LA Habel et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306:2673.
- H Schelleman et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127:1102.
- SA Shahani et al. Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective. Pediatr Cardiol 2014; 35:485.
- LS Eiland et al. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. Ann Pharmcother 2014; 48:1350.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019; November 6 (epub). Available at medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- ST Osland et al. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2018, 6:CD007990.
- Guanfacine extended-release (Intuniv) for ADHD. Med Lett Drugs Ther 2010; 52:82.
- Another extended-release alpha2-agonist for ADHD. Med Lett Drugs Ther 2011; 53:10.
- Atomoxetine (Strattera) for ADHD. Med Lett Drugs Ther 2003; 45:11.
- JH Newcorn et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165:721.
- T Treuer et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol 2013; 23:179.
- VA Reed et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs 2016; 30:603.
- KF Huybrechts et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2018; 75:167.
- C Andrade. Risk of major congenital malformations associated with the use of methylphenidate or amphetamines in pregnancy. J Clin Psychiatry 2018; 79(1):18f12108.
- JM Cohen et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol 2017; 130:1192.
- C Andrade. Adverse gestational outcomes associated with attention-deficit/hyperactivity disorder medication exposure during pregnancy. J Clin Psychiatry 2018; 79(1):18f12136.
- S Cortese et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psycyiatry 2018; 5:727.
- JJ McGough et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2019; 58:403.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.